Acer therapeutics announces full enrollment of phase 2a trial of acer-801 (osanetant) for treatment of moderate to severe vasomotor symptoms associated with menopause

Topline trial results expected mid-march 2023 topline trial results expected mid-march 2023

ACER Ratings Summary

ACER Quant Ranking